Pub. Date : 2015 Nov
PMID : 26389554
17 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 2 | Cytochrome P4502B6 (CYP2B6) is the principle determinant of clinical methadone elimination. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 3 | CYP2B6.6, the protein encoded by the CYP2B6*6 polymorphism, deficiently catalyzes methadone metabolism in vitro. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 4 | CYP2B6.6, the protein encoded by the CYP2B6*6 polymorphism, deficiently catalyzes methadone metabolism in vitro. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 5 | This investigation determined the influence of CYP2B6*6, and other allelic variants encountered, on methadone concentrations, clearance, and metabolism. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 6 | RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 7 | RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 8 | RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 9 | R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 10 | R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 11 | R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 12 | Methadone metabolism and clearance were lower in African Americans in part because of the CYP2B6*6 genetic polymorphism. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 13 | CONCLUSIONS: CYP2B6 polymorphisms influence methadone plasma concentrations, because of altered methadone metabolism and thus clearance. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 14 | CONCLUSIONS: CYP2B6 polymorphisms influence methadone plasma concentrations, because of altered methadone metabolism and thus clearance. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 15 | CYP2B6 pharmacogenetics explains, in part, interindividual variability in methadone elimination. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 16 | CYP2B6 genetic effects on methadone metabolism and clearance may identify subjects at risk for methadone toxicity and drug interactions. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |
| 17 | CYP2B6 genetic effects on methadone metabolism and clearance may identify subjects at risk for methadone toxicity and drug interactions. | Methadone | cytochrome P450 family 2 subfamily B member 6 | Homo sapiens |